Valuation: VISD GP

Market Cap 54.95M 62.86M 50.5M 47.07M 89.28M 5.99B 90.64M 606M 236M 2.94B 236M 231M 10.14B P/E 2024
44.3x
P/E 2025 31.3x
Enterprise Value 55.08M 63M 50.61M 47.18M 89.48M 6B 90.84M 608M 236M 2.95B 236M 231M 10.16B EV / Sales 2024
3.3x
EV / Sales 2025 3.04x
Free-Float
99.83%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 36 2024-01-21
Investor Relations Contact - -
Chief Executive Officer - 2022-03-31
Director TitleAgeSince
Chairman - -
Director/Board Member - 2022-03-31
Director/Board Member 51 2023-06-13
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%+0.36%+55.30%+50.48% 134B
+4.39%+4.80%+9.01%+37.59% 91.07B
+1.14%+8.92%+1.25%+73.51% 27.34B
-0.14%+2.78%+21.93%+56.09% 23.88B
+0.09%+3.18%-19.07%-24.15% 20.28B
+6.55%+7.79%+18.79%+153.04% 17.55B
+0.62%+3.00%+2.35%+11.27% 15.2B
+3.02%+8.23%+64.78%+131.76% 15.08B
+0.84%+4.65%-13.64%-3.41% 12.63B
Average +1.46%+4.88%+15.63%+54.02% 39.63B
Weighted average by Cap. +1.47%+3.62%+26.78%+49.99%

Financials

2024 2025
Net sales 17.26M 19.74M 15.86M 14.79M 28.04M 1.88B 28.47M 190M 74.03M 924M 74.11M 72.52M 3.18B 22.17M 25.36M 20.37M 18.99M 36.01M 2.41B 36.56M 245M 95.07M 1.19B 95.18M 93.13M 4.09B
Net income 1.4M 1.61M 1.29M 1.2M 2.28M 153M 2.32M 15.5M 6.03M 75.22M 6.03M 5.9M 259M 2.28M 2.61M 2.1M 1.95M 3.71M 248M 3.76M 25.17M 9.78M 122M 9.79M 9.58M 421M
Net Debt 2.58M 2.95M 2.37M 2.21M 4.18M 280M 4.25M 28.41M 11.04M 138M 11.06M 10.82M 475M 125K 143K 115K 107K 203K 13.61M 206K 1.38M 536K 6.69M 537K 525K 23.06M
Logo VISD GP
Founded in 2007, Klea Holding is a group focused on acquiring, developing and digitizing companies in various sectors to maximize their growth and value. Through its "scaling industries of the future" identity, Klea Holding draws on its successful experience in developing Smart Salem, the first network of digitalized medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates, its joint venture Smart Health, dedicated to the roll-out of digital medical testing centres in Saudi Arabia; and Klea Pharmaceuticals, a subsidiary dedicated to the commercialisation of a portfolio of licensed medicines in the Middle East and Africa.
Employees
-